Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review
Systematic Reviews volume 8, Article number: 132 (2019)
Cervical cancer is a major public health issue in the world, especially in developing countries. It can be prevented through vaccination against HPV (primary prevention) and through screening and treatment of cervical intraepithelial neoplasia (CIN) (secondary prevention). Surgical methods for treatment of CIN are linked to complications such as bleeding and adverse pregnancy outcomes. Furthermore, these methods are not generally available in resource-poor settings. Therefore, topical agents for local application on the cervix have been used since decades to overpass complications and limitations of the surgical methods.
Review of the literature on the efficacy of commercially available biological agents used for topical treatment of cervical intraepithelial neoplasia (CIN).
A systematic search through PubMed and the Cochrane database was performed up to December 2017, using the medical subheadings (MesH) for topical agent, treatment, and cervical intraepithelial neoplasia. Appropriate inclusion/exclusion criteria have been used for the selection of eligible clinical studies. Clinical studies containing a minimum of 20 women, aged 18–50 with a diagnosis of CIN 1–3, and at least a 4 weeks follow-up after the end of the topical treatment were included.
The initial electronic database search resulted in a total of 849 articles. After screening titles and abstracts, 62 articles were selected as potential studies. Of these, six articles were included in the review after reading the full text: two were on 5-FluoroUracil, two on trans retinoic acid, one on Imiquimod, and one on Cidofovir. The reported regression/remission rates for CIN differed among studies. In CIN2 patients, the overall remission rate ranged between 43 and 93% for the active agents.
Among the topical agents studied, 5-FluoroUracil showed good remission rates above 80%. Varying results seen in this review is due to the differences in quality of the design between studies. Large-scale and less biaised studies are needed to elucidate the true efficacy and safety of topical agents in the treatment of CIN.
Cervical cancer (CC) develops through several, easily detectable precancerous stages. Detection and treatment of the precancerous stages constitutes the mainstay of secondary cervical cancer prevention. Despite the proven efficacy of this secondary prevention, CC continues to be a major public health problem among women globally. Each year, over 500.000 women are diagnosed with CC worldwide, with 266,000 related deaths; making it the fourth most common cancer among women .
The precursor lesion for CC is called cervical intraepithelial neoplasia (CIN) or dysplasia. Agreement between the cytological Bethesda system classification and a histological result is as follows: low-grade squamous intraepithelial lesion (LSIL) in The Bethesda System (TBS) is encompassing human papillomavirus (HPV)/mild dysplasia (CIN1), while high-grade squamous intraepithelial lesions (HSIL) is encompassing moderate and severe dysplasia (CIN2 and CIN3) . CIN is induced by a sexually transmitted infection with an oncogenic strain of the HPV [3, 4]. When persisting, it can progress to cervical cancer over a period of 7 to 20 years . With cytological screening, classified by TBS, low- or high-grade lesions can be detected, and used for referral for further histological diagnosis. Histological examination of whole tissues allows several other features to be examined: differentiation, maturation and stratification of cells, and nuclear abnormalities. Nuclear abnormalities such as enlarged nuclei, increased nuclear-cytoplasmic ratio, increased intensity of nuclear staining (hyperchromasia), nuclear polymorphism, and variation in nuclear size (anisokaryosis) are assessed when a diagnosis of CIN is being made. The proportion of the thickness of the epithelium showing mature and differentiated cells is used for grading CIN. According to the height of affected cells within the stratified epithelium, dysplasia is classified as mild (CIN1), moderate (CIN2), or severe (CIN3). Cervical cancer can be prevented through HPV vaccination (primary prevention) and through screening and treatment for CIN and early invasive cervical cancer (secondary prevention).
Until a few years ago, the only method of screening for cervical cancer was the Papanicolaou (“Pap”) smear or cytology. In high-income countries, where Pap smears have been used for population-based screening for over three decades, there has been a major reduction in morbidity and mortality from cervical cancer . However, population-based cytology screening in low- and middle-income countries is often unsuccessful because the financial investments to establish and maintain the necessary level of health infrastructure, including laboratory and skilled human resources, are not available or not sufficient in many settings. Newer methods have been developed for cervical cancer screening: molecular HPV screening tests and visual inspection with acetic acid. Molecular HPV testing methods are based on the detection of deoxyribonucleic acid (DNA)/ribonucleic acid (RNA) from high-risk HPV types in vaginal and/or cervical samples. Visual inspection with acetic acid (VIA) is a method for detecting early cell changes that are visible when using a speculum to inspect the cervix with the naked eye after applying dilute (3–5%) acetic acid to it.
When a precursor lesion of CC is detected during screening, effective treatment and follow-up is necessary. The current surgical treatment options for CIN fall into two main categories: procedures that either ablate the abnormal tissue or procedures that excise the area of abnormality. The most common ablative techniques for the treatment of CIN include cryotherapy, laser ablation, and thermocoagulation. The excisional procedures include cold knife conization, laser cone excision, and loop electrosurgical excision procedure (LEEP). Controlled trials show 80–90% success rates in the treatment of CIN, regardless of treatment modality used [7,8,9]. In the vast majority of cases, treatments used for CIN are mainly excisional procedures. Possible complications of surgical treatment modalities include cervical stenosis, alteration of the cervical mucus, and removal or destruction of the collagen matrix of the cervical stroma. This can impact future pregnancies with an increased risk for preterm delivery and its associated neonatal mortality . Furthermore, surgical procedures may present major difficulties in low- and middle-income countries as electrical current or a continuous supply of medical gasses (carbon dioxide or nitrogen) is needed . Non-surgical topical CIN therapies do not yield these complications and limitations. These therapies retard tumor growth and stimulate the immune response to viruses, leading to the regression of CIN lesions . Table 1 alphabetically lists the nine commercially available biological agents and their mechanism of action used for topical treatment. There are some other agents that have been experimented in the local treatment of CIN: betulinic acid , belonging to the class of organic compounds known as triterpenoids; glycyrrhizinic acid , a triterpene glycoside compound extracted from the root of the licorice plant Glycyrrhiza glabra; and Praneem , a polyherbal formulation that has successfully completed phase II efficacy study for the treatment of abnormal vaginal discharge due to reproductive tract infections that act as co-factors for HPV persistence.
This review is meant to evaluate the efficacy of these non-surgical commercially available topical therapies used to treat CIN lesions.
Inclusion and exclusion criteria
Reports of clinical trials assessing the effect of topical treatment were included, regardless of the publication language, and containing a minimum of 20 women, with the following inclusion criteria: CIN 1 to 3, aged 18–50 and at least a 4-week follow-up after the end of topical treatment. The diagnostic method and the post-treatment assessment were by cytology or histology. Publications were excluded if CIN was not well-documented, the disease studied was a cancer or an intraepithelial neoplasia other than cervical, when surgical therapy alone or in combination with a topical agent was used, or the recipe or drug was not used topically. Studies not using commercially available preparations were also excluded.
The main outcome was the efficacy of the topical drug administered. Efficacy is expressed in terms of regression of the CIN lesion on post-treatment colposcopy or histology examination.
Regression is defined as improvement from CIN3 to CIN2 or CIN1 or normal, from CIN2 to CIN1 or normal, and from CIN1 to normal. Regression can be partial or complete. Complete regression, also called remission, is defined as a total disappearance of the CIN lesion or improvement from any grade of CIN (CIN 1, CIN 2, or CIN 3) to no CIN.
Search strategy and selection of studies
Bibliographic databases (PubMed and Cochrane database) were searched up to December 2017 using a predefined search strategy (see below). In addition, the authors screened the reference lists of identified articles. The search strategy, based on a combination of relevant medical subheadings (MeSH), text words and word variants for topical, therapy, cervix, and neoplasia were utilized. The PubMed database was searched using the following key words: ((“Topical” OR “local”) AND therapy) AND ((“CIN” OR “cervical intraepithelial neoplasia” OR “SIL” OR “ squamous intraepithelial lesion” OR “neopl*” OR “dyspl*”) AND (“cervix” OR “cervical”)) NOT animals. The Cochrane database as well was searched, using the same strategy. Two review authors (AMB, YJ) independently screened the titles and abstracts of references identified by the electronic searches to identify publications of potentially eligible trials. These trials were assessed for inclusion in the review and discrepancies in eligibility judgements were resolved by discussion. To rate the agreement between the first and second reviewer in selecting the studies for this review, Kappa statistics was calculated. This was based on comparing the number of observed agreements with the number of agreements that would expected simply by chance, using Microsoft Excel® software. The strength of agreement is considered to be “good” when kappa values are between 0.4 and 0.75 and “excellent” when kappa ≥ 0.75. The review selection criteria were applied to each identified record and exclusion of potentially eligible studies was reported in the PRISMA diagram.
Data extraction and management
Data from published trial reports were extracted and entered onto an electronic form (using Microsoft Excel®). Authors, year of publication, country, type of study, topical agent, severity of disease, diagnostic method, number of subjects (per protocol population), treatment regimens, placebo (if applicable), delivery system (and administrator), length of follow-up after the end of the treatment, and regression/remission rate have been tabulated.
The methodological quality of the included studies was evaluated according to Cochrane collaboration’s tool for assessing risk of bias for randomized clinical trials (RCTs) . The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was applied to assess the certainty of evidence across studies . The details for these assessments will be presented in the Additional file 2.
The initial search yielded 849 papers, of which 13 duplicates were removed. Out of 836 potentially relevant papers, 62 were maintained for further analysis based on the title and abstract. Six of these met the inclusion criteria and were included in the final descriptive analysis (Fig. 1: search flow diagram). Checking the reference lists of included studies and published reviews yielded no additional studies. The agreement between the reviewers in selecting these articles after applying the inclusion and exclusion criteria was analyzed with a kappa statistic, which resulted in a value of 0.90 (95% CI 0.87–0.93). The characteristics of the individual included studies are presented in Table 2. An important observation is that all the included studies originate from high-income countries. Most of them were randomized clinical trials, published between 1991 and 2014. The included studies were of varying methodology and were predominantly performed in a secondary screening setting. To highlight the risk of bias, the Cochrane risk of bias tool was utilized for the included studies. According to this, these studies were considered to be high quality (Additional file 1). Overall, the certainty of evidence across these studies was reported to be of moderate level for one intervention to low level for the remaining interventions (Additional file 2).
Among the commercially available agents, the more frequently studied were 5-FluoroUracil (5-FU), Cidofovir 2%, Imiquimod 5%, and all-trans retinoic acid (atRA).
Considering clinical heterogeneity, pooling of data was not possible. Instead, a best evidence synthesis for histological, colposcopic, or cytologic regression or remission was compiled. The treatment regimen and regression/remission rates are summarized in Table 3.
Two studies involved topical 5-FU in 149 CIN1–2 women [13, 14]. In the study by Sidhu et al., the regression rate was 67% in the 5-FU-treated group compared to 72% in the placebo group (p = 0.76) (no remission data available) . However, Rahangdale et al. reported regression rates of 93% (86% remission) in the 5-FU-treated group compared to 56% (44% remission) in the control group (= observation) (p = 0.01) . The treatment schedule, delivery system, and follow-up time completely differed between the two studies.
Another two papers [28, 29] reported on the efficacy of trans-retinoic acid treatment in 406 women with lesions. Both studies showed comparable results for equal concentrations of atRA (0.375% and 0.36%), although the number of applications and follow-up time were very diverse. The remission rates were 43% and 50% for CIN2 lesions, and 25% and 14% for CIN3 patients, in the Meyskens and Ruffin study respectively. A huge difference in remission could be noticed between the placebo controls in both studies (24% remission (15) versus 62% (16) for CIN2 lesions), and atRA was therefore judged no more effective than placebo in the Ruffin study. Lower concentrations of atRA (0.16–0.28%) showed better remission in the CIN3 (44–50%) study group compared to the 0.36% of atRA (16).
In small study set ups (48 and 55 women, respectively), the reported remission of grouped CIN2–3 cases was 61% for Cidofovir (versus 20% for placebo) (p = 0.01) and 50% for Imiquimod (versus 15% for placebo) (p = 0.08) [16, 30].
No moderate or severe side effects related to drug or placebo exposure were reported, except in the study by Meyskens et al. in 1994, where mild and reversible vaginal and vulvar side effects were seen in the patients receiving retinoic acid . An overview on the studies which were excluded after full-text review and reasons for exclusion are presented in Table 4. Most of the excluded papers were about what is called photodynamic therapy which does not act as a biological agent [31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46].
During the last two decades, topical biological agents have been studied as alternatives to surgical methods for the management of cervical intraepithelial neoplasia (CIN). The objective of this review was to report on the efficacy of commercially available topical drugs used in the treatment of CIN. A total of six studies fulfilling all the inclusion criteria were retained for this review. They reported on 5-FluoroUracil [13, 14], all-trans retinoic acid [28, 29], Imiquimod , and Cidofovir . Although this number was relatively low, our inclusion criteria focused on the commercially available drugs and on randomized clinical studies. The reported agents in the present review have been shown efficacious in clinical regression of CIN. Regression rates, however, differ among studies. One of the reasons for that is their varying methodological design and therapeutic schemes. Considering the results in their globality, we strive to find that each of the agents does produce regression or remission regardless of the regimen or the method employed for diagnosis or follow-up. In general, remission ranged between 43 and 93% for the active agents in CIN2 patients.
5-Fluorouracil is a pyrimidine analogue which acts through inhibition of the target enzyme thymidylate synthase (TS) by the 5-FU metabolite, FdUMP, and incorporation of this metabolite into DNA, resulting in inhibition of DNA synthesis and function. It stops the cells making and repairing DNA. Topical 5-FU appears to be an effective medical therapy for CIN [13, 14]. Although 5-FluoroUracil resulted in 93% regression versus 56% for placebo in the study by Rahangdale et al. , Sidhu et al.  found a regression of 67% for 5-FluoroUracil less efficacious compared to placebo (72%). The latest was a double-blind randomized controlled trial while the study by Rahangdale et al. was a prospective but nonblinded randomized trial of 5-FU versus standard-of-care observation (no placebo). The difference in the methodology and the regimen (one versus eight applications) can explain the discrepant results between these studies. Although Rahangdale et al. deliberately did not use a placebo to avoid interfering with the natural regression of CIN, this has constituted a limitation. Furthermore, this study introduced bias since the investigator, in a clinical setting, was not blind to the randomization allocation and could have been influenced in performing colposcopically directed biopsies, resulting in wrong diagnoses. The high spontaneous regression rate of CIN in the placebo group found by Sidhu et al. and Rahangdale et al. can be explained by the fact that patients with CIN3 lesions were excluded from these studies, thus allowing background spontaneous regression to be a confounding variable. Further on, the cytotoxic drug delivery system used in the Sidhu trial could have altered the pH at the cervical epithelium and this may have been sufficient to cause cell death, resulting in the clearance of the lesion.
Retinoids are essential for cell growth, differentiation, and cell death. Various retinoids have been shown to inhibit cellular proliferation in cervical cancer cells in several studies. All-trans retinoic acid (atRA) is an active metabolite of vitamin A under the family retinoid. Retinoids, through their cognate nuclear receptors, exert potent effects on cell growth, differentiation, and apoptosis. Retinoic acid either decreases or increases EGF-stimulated growth and epidermal growth factor-receptor (EGF-R) expression depending on the cell line and culture conditions. HPV-containing cell lines overexpress EGF-R and are more sensitive to retinoids than normal cells. Increased sensitivity of HPV-containing cells may explain the reversal of premalignant lesions and dysplasias of the cervix by retinoic acid . In a study on all-trans retinoic acid by Ruffin et al. , the rate of histologic remission in biopsied CIN II patients was 50% (0.36% atRA) over a short treatment time of 4 days (FU time = 11 weeks), but no difference with the remission rate in the placebo controls (62%) could be observed, judging the atRA treatment as no more effective than placebo treatment. In the study by Meykens et al. , a comparable remission of 43% (0.375% atRA) was obtained with a double amount of applications and a much longer follow up time (21 months). It was suggested in this study that locally applied RA could favorably alter the natural history of CIN if the lesion had not progressed too far (no difference between RA and placebo in CIN3 patients). The authors hypothesized that this significant regression rate—compared to their placebo control (only 27% remission)—could be explained by the fact that RA has been an effective inhibitor of growth and stimulator of differentiation in cervical tissue by producing immunologic and inflammatory responses. An important constatation is that lower concentrations of atRA (0.16% and 0.28%) gave better results in the CIN3 patient group (44% and 50% regression, respectively, compared to 14% for the higher atRA concentration of 0.36%) .
For some agents, only one study could be retrieved for this systematic review. Imiquimod is an immunomodulator with antiviral and anti-tumor effects. It is a toll-like receptor 7 agonist and induces upregulation of interferon and activation of dendritic cells. Imiquimod (5% cream) has been shown to be safe and effective in the treatment of genital warts caused by low-risk HPV infections. The mechanism for the eradication of genital verrucous lesions with imiquimod may involve the induction of both innate and cellular immunity. Antiviral activity may be stimulated through the induction of cytokines, such as interferon-a (IFN-a), tumor necrosis factor-a (TNF-a), and interleukins (ILs) [18, 19]. In a randomized, double-blind, placebo-controlled phase II trial of Imiquimod, the histologic remission of 50% was significantly higher than the 15% in the placebo-controls. Topical, patient-applied, vaginal imiquimod therapy was therefore demonstrated to be an efficacious treatment option for CIN2–3 patients in this study. The most important shortcoming was the very short follow-up after the completion of the full treatment (4 weeks), warranting a study with a longer follow-up period . A new study is on its way, whose purposes are to test the treatment efficacy hypothesis as well as long-term disease recurrence after treatment and clinical applicability of imiquimod treatment, and to develop a prediction model for clinical response to Imiquimod treatment, based on histological biomarkers .
Cidofovir, an acyclic phosphonate nucleoside with a broad-spectrum activity against DNA viruses, has proved efficacious in the treatment of different clinical manifestations of HPV-induced epithelial cell proliferation. As an antiviral drug, it is incorporated in viral DNA and preferentially inhibits DNA, reduce capacity of HPV positive cells to repair DNA damage. It is recognized as one of the effective treatments for several HPV-induced lesions [17, 48]. Cidofovir 1% gel is able to inhibit partially or completely cervical dysplasia lesions [16, 17] . In a study by Van Pachterbeke et al., cidofovir was shown to be active against CIN2+ lesions in immunocompetent women. In this study, histological clearance was demonstrated in 61% compared with 20% in the placebo group. The failure to regress completely may be due to insufficient penetration to all targeted cells, to the frequency of administration of the product during the study, or to the severity of the lesion. The short observation time of 6 weeks was again an important weakness. Most of the studies analyzing the data after a longer period (3 to 6 months) provided more complete responses . Thus, it has to be verified whether a prolonged exposure to topical drugs could provide better outcomes. The last two studies grouped the results of CIN2 and CIN3 patients together, so higher remission rates can be expected in an exclusively CIN2 population with Imiquimod and Cidofovir, based on the varying remissions according to the grade of CIN in the studies with separate CIN2 and CIN3 data [16, 30].
Although the six studies included in this systematic review provided evidence to allow conclusions to be drawn, the review has several limitations. The treatment doses and regimen and the length of follow-up varied among studies. This also made it difficult to pool the results for the included studies. Differences in populations and stages of CIN made comparisons among studies challenging. Therefore, further large-scale, rigorous RCTs with consistent inclusion criteria, design, and outcomes are warranted to ascertain the efficiency of the different treatment approaches.
To conclude, regression results for the reported topical agents were discrepant between studies. 5-FluoroUracil has provided good results in term of CIN remission. Moreover, the latter is known to be a very active anticancer drug used in chemotherapy for various types of invasive neoplasms. In the framework of secondary prevention, topical therapies can play an important role as they may help in safely treating precancerous lesions without resorting to surgical methods. This is a great advantage because surgical methods may have many complications in the short and long term. Another advantage of the topical drugs reviewed here is their ability to be stored at room temperature, thus not requiring cold chain, as it is known that in developing countries, the cold chain may be interrupted due to non-availability of electrical current. This allows their proper use in low- and middle-income countries (LMICs) when they need to come from abroad or when they should be stored for a long time in rural areas.
The efficacy of topical agents in the studies reviewed were variable depending on the agent and methodology employed. Cidofovir, Imiquimod, all-trans retinoic acid, and 5-FluoroUracil have been proposed as agents for topical treatment of CIN lesions. Overall, the remission rates of CIN2 ranged from 43 to 93%. However, sometimes results have been contradictory for a given agent. One of the explanations is that the methodology and the regimen employed are different from one study to another. Hence, to shed light on the true efficacy of these topical agents, large-scale, multicentric, and less biased studies are necessary. When proved effective, the topical agents could advantageously be used as an alternative to surgery in treating HPV-associated precancerous lesions of the cervix, especially for the LMICs.
All-trans retinoic acid
Cervical intraepithelial neoplasia
Epidermal growth factor-receptor
Intention to treat
Loop electroexcision procedure
Low- and middle-income countries
Million international units
Randomized clinical trial
The Bethesda System
United States of America
Visual inspection with acetic acid
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
Sellors J, Sankaranarayanan R. Colposcopy and treatment of cervical intraepithelial neoplasia: a beginners’manual. Lyon: International Agency for Research on Cancer; 2003.
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer. 2002;2:342–50.
Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(Suppl 3):S3/42–51.
Mathew A, George PS. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix—worldwide. Asian Pac J Cancer Prev. 2009;10:645–50.
Wong SP, Fung YM, Wong WS. A prospective study of the treatment of cervical intraepithelial neoplasia by loop electrosurgical excision procedure (LEEP) in Hong Kong population. Asia Oceania J Obstet Gynaecol. 1994;20:289–93.
Wongtiraporn W, Laiwejpithaya S, Sangkarat S, et al. Long term outcomes of laser conization for high grade cervical intraepithelial neoplasia in Thai women. Asian Pac J Cancer Prev. 2014;15:7757–61.
Woodman CB, Byrne P, Kelly KA, Hilton C. A randomized trial of laser vaporization in the management of cervical intraepithelial neoplasia associated with human papilloma virus infection. J Public Health Med. 1993;15:327–31.
Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.
Sauvaget C, Muwonge R, Sankaranarayanan R. Meta-analysis of the effectiveness of cryotherapy in the treatment of cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2013;120:218–23.
Bharti AC, Shukla S, Mahata S, et al. Anti-human papillomavirus therapeutics: facts & future. Indian J Med Res. 2009;130:296–310.
Rahangdale L, Lippmann QK, Garcia K, et al. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. Am J Obstet Gynecol. 2014;210:314. e311–318
Sidhu HK, Price JH, McCarron PA, et al. A randomised controlled trial evaluating a novel cytotoxic drug delivery system for the treatment of cervical intraepithelial neoplasia. Br J Obstet Gynaecol. 1997;104:145–9.
Laccetta G, Carrone A, Burratti M, Mancino P. Effect of the treatment with beta-glucan in women with cervical cytologic report of atypical squamous cells of undetermined significance (ASCUS) and low-grade squamous intraepithelial lesions (L-SIL). Minerva Ginecol. 2015;67:113–20.
Van Pachterbeke C, Bucella D, Rozenberg S, et al. Topical treatment of CIN 2+ by cidofovir: results of a phase II, double-blind, prospective, placebo-controlled study. Gynecol Oncol. 2009;115:69–74.
Snoeck R, Noel JC, Muller C, et al. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III). J Med Virol. 2000;60:205–9.
Diaz-Arrastia C, Arany I, Robazetti SC, et al. Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. Clin Cancer Res. 2001;7:3031–3.
Stary G, Bangert C, Tauber M, et al. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med. 2007;204:1441–51.
Cinel A, Wittenberg L, Minucci D. Beta-interferon topical treatment in low and high risk cervical lesions. Clin Exp Obstet Gynecol. 1991;18:91–7.
Grismondi GL, Masin G, Marini A. Beta-interferon in the therapy of cervico-vaginal papilloma virus (HPV) infection associated with cervical intraepithelial neoplasia (CIN). Minerva Ginecol. 1995;47:527–9.
Benbrook DM, Lu S, Flanagan C, et al. Biological assay for activity and molecular mechanism of retinoids in cervical tumor cells. Gynecol Oncol. 1997;66:114–21.
Schettino MT, Ammaturo FP, Labriola D, et al. Betulinic acid and possible influence on the clearance of human papilloma virus: cytological and virological follow-up. Minerva Ginecol. 2013;65:661–8.
Valencia MH, Pacheco AC, Quijano TH, et al. Clinical response to glycyrrhizinic acid in genital infection due to human papillomavirus and low-grade squamous intraepithelial lesion. Clin Pract. 2011;1:e93.
Shukla S, Bharti AC, Hussain S, et al. Elimination of high-risk human papillomavirus type HPV16 infection by 'Praneem' polyherbal tablet in women with early cervical intraepithelial lesions. J Cancer Res Clin Oncol. 2009;135:1701–9.
Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6.
Meyskens FL Jr, Surwit E, Moon TE, et al. Enhancement of regression of cervical intraepithelial neoplasia II (moderate dysplasia) with topically applied all-trans-retinoic acid: a randomized trial. J Natl Cancer Inst. 1994;86:539–43.
Ruffin MT, Bailey JM, Normolle DP, et al. Low-dose topical delivery of all-trans retinoic acid for cervical intraepithelial neoplasia II and III. Cancer Epidemiol Biomark Prev. 2004;13:2148–52.
Grimm C, Polterauer S, Natter C, et al. Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. Obstet Gynecol. 2012;120:152–9.
Barnett AA, Haller JC, Cairnduff F, et al. A randomised, double-blind, placebo-controlled trial of photodynamic therapy using 5-aminolaevulinic acid for the treatment of cervical intraepithelial neoplasia. Int J Cancer. 2003;103:829–32.
Choi MC, Jung SG, Park H, et al. Photodynamic therapy for management of cervical intraepithelial neoplasia II and III in young patients and obstetric outcomes. Lasers Surg Med. 2013;45:564–72.
Choi MC, Lee C, Kim SJ. Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia: a systemic review. Photodiagn Photodyn Ther. 2014;11:479–80.
Fu Y, Bao Y, Hui Y, et al. Topical photodynamic therapy with 5-aminolevulinic acid for cervical high-risk HPV infection. Photodiagn Photodyn Ther. 2016;13:29–33.
Hillemanns P, Einstein MH, Iversen OE. Topical hexaminolevulinate photodynamic therapy for the treatment of persistent human papilloma virus infections and cervical intraepithelial neoplasia. Expert Opin Investig Drugs. 2015;24:273–81.
Hillemanns P, Garcia F, Petry KU, et al. A randomized study of hexaminolevulinate photodynamic therapy in patients with cervical intraepithelial neoplasia 1/2. Am J Obstet Gynecol. 2015;212:465.e461–7.
Hillemanns P, Korell M, Schmitt-Sody M, et al. Photodynamic therapy in women with cervical intraepithelial neoplasia using topically applied 5-aminolevulinic acid. Int J Cancer. 1999;81:34–8.
Hillemanns P, Petry KU, Soergel P, et al. Efficacy and safety of hexaminolevulinate photodynamic therapy in patients with low-grade cervical intraepithelial neoplasia. Lasers Surg Med. 2014;46:456–61.
Hillemanns P, Wang X, Hertel H, et al. Pharmacokinetics and selectivity of porphyrin synthesis after topical application of hexaminolevulinate in patients with cervical intraepithelial neoplasia. Am J Obstet Gynecol. 2008;198:300. e301–307
Monk BJ, Brewer C, VanNostrand K, et al. Photodynamic therapy using topically applied dihematoporphyrin ether in the treatment of cervical intraepithelial neoplasia. Gynecol Oncol. 1997;64:70–5.
Pahernik SA, Botzlar A, Hillemanns P, et al. Pharmacokinetics and selectivity of aminolevulinic acid-induced porphyrin synthesis in patients with cervical intra-epithelial neoplasia. Int J Cancer. 1998;78:310–4.
Soergel P, Loehr-Schulz R, Hillemanns M, et al. Effects of photodynamic therapy using topical applied hexylaminolevulinate and methylaminolevulinate upon the integrity of cervical epithelium. Lasers Surg Med. 2010;42:624–30.
Soergel P, Loning M, Staboulidou I, et al. Photodynamic diagnosis and therapy in gynecology. J Environ Pathol Toxicol Oncol. 2008;27:307–20.
Tao XH, Guan Y, Shao D, et al. Efficacy and safety of photodynamic therapy for cervical intraepithelial neoplasia: a systemic review. Photodiagn Photodyn Ther. 2014;11:104–12.
Wang J, Xu J, Chen J, et al. Successful photodynamic therapy with topical 5-aminolevulinic acid for five cases of cervical intraepithelial neoplasia. Arch Gynecol Obstet. 2010;282:307–12.
Yamaguchi S, Tsuda H, Takemori M, et al. Photodynamic therapy for cervical intraepithelial neoplasia. Oncology. 2005;69:110–6.
Koeneman MM, Kruse AJ, Kooreman LF, et al. TOPical Imiquimod treatment of high-grade cervical intraepithelial neoplasia (TOPIC trial): study protocol for a randomized controlled trial. BMC Cancer. 2016;16:132.
Snoeck R, Andrei G, De Clercq E. Cidofovir in the treatment of HPV-associated lesions. Verh K Acad Geneeskd Belg. 2001;63:93–120. discussion 120-122
No external funding.
Availability of data and materials
Ethics approval and consent to participate
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mutombo, A.B., Simoens, C., Tozin, R. et al. Efficacy of commercially available biological agents for the topical treatment of cervical intraepithelial neoplasia: a systematic review. Syst Rev 8, 132 (2019). https://doi.org/10.1186/s13643-019-1050-4